Stroke, antithrombotic, pulmonary embolism, monoclonal antibody

Acticor Biotech (http://acticor-biotech.com/en/) is a biopharmaceutical company, spin-off of Inserm, founded late 2013. Its lead candidate
ACT017 is being developed for the treatment of the acute phase of ischemic stroke as an add-on treatment to Activase®
(rtPA) / thrombectomy or for non-eligible patients to rtPA treatment. ACT017 is a humanized Antibody Fragment (Fab), directed against
platelet glycoprotein VI (GPVI) and inhibiting its action.

Acticor biotech is entering in a first phase II clinical study in the acute phase of ischemic stroke.